CHI Advisors’s Blueprint Medicines BPMC Stock Holding History

CHI Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$4.66M	Buy	+92,888	New	+$4.96M	1.85%	14
2021 Q2	–	Sell	-3,500	Closed	-$340K	–	20
2021 Q1	$340K	Sell	3,500 -2,000	-36%	-$200K	0.07%	20
2020 Q4	$617K	Sell	5,500 -1,000	-15%	-$105K	0.17%	18
2020 Q3	$603K	Sell	6,500 -5,500	-46%	-$424K	0.21%	19
2020 Q2	$936K	Sell	12,000 -24,000	-67%	-$1.62M	0.37%	16
2020 Q1	$2.1M	Buy	36,000 +10,000	+38%	+$644K	4.96%	5
2019 Q4	$2.08M	Buy	26,000 +8,000	+44%	+$599K	1.57%	5
2019 Q3	$1.32M	Buy	+18,000	New	+$1.56M	1.29%	6

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CHI Advisors's BPMC Position: Q3 2023 in Review

CHI Advisors opened a new position in Blueprint Medicines (BPMC) in Q3 2023: 92,888 shares worth $4.66M. The stake represents 1.85% of the portfolio and ranks #14 among its holdings. This is a return to the name: CHI Advisors previously reported a position in BPMC as recently as Q1 2021.

CHI Advisors first reported a position in BPMC in Q3 2019 and has held it in 8 quarters since. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2023.

CHI Advisors held 92,888 shares of Blueprint Medicines worth $4.66M as of Q3 2023.
Blueprint Medicines was a new CHI Advisors position in Q3 2023.
Blueprint Medicines made up 1.85% of CHI Advisors's portfolio in Q3 2023, its #14 holding.
CHI Advisors first reported a position in Blueprint Medicines in Q3 2019 and has held it in 8 quarters since.
220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2023.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.